Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia

Samuel Dunyo, Giorgio Sirugo, Sanie Sesay, Cyrille Bisseye, Fanta Njie, Majidah Adiamoh, Davis Nwakanma, Mathurin Diatta, Ramatoulie Janha, Fatou Sisay Joof, Beth Temple, Paul Snell, David Conway, Robert Walton, Yin Bun Cheung, Paul Milligan, Samuel Dunyo, Giorgio Sirugo, Sanie Sesay, Cyrille Bisseye, Fanta Njie, Majidah Adiamoh, Davis Nwakanma, Mathurin Diatta, Ramatoulie Janha, Fatou Sisay Joof, Beth Temple, Paul Snell, David Conway, Robert Walton, Yin Bun Cheung, Paul Milligan

Abstract

Background: Chlorproguanil-dapsone (Lapdap), developed as a low-cost antimalarial, was withdrawn in 2008 after concerns about safety in G6PD deficient patients. This trial was conducted in 2004 to evaluate the safety and effectiveness of CD and comparison with artemether-lumefantrine (AL) under conditions of routine use in G6PD normal and G6PD deficient patients with uncomplicated malaria in The Gambia. We also examined the effects of a common genetic variant that affects chlorproguanil metabolism on risk of treatment failure.

Methods: 1238 children aged 6 months to 10 years with uncomplicated malaria were randomized to receive CD or artemether-lumefantrine (AL) and followed for 28 days. The first dose was supervised, subsequent doses given unsupervised at home. G6PD genotype was determined to assess the interaction between treatment and G6PD status in their effects on anaemia. The main endpoints were clinical treatment failure by day 28, incidence of severe anaemia (Hb<5 g/dL), and haemoglobin concentration on day 3.

Findings: One third of patients treated with AL, and 6% of patients treated with CD, did not complete their course of medication. 18% (109/595) of children treated with CD and 6.1% (36/587) with AL required rescue medication within 4 weeks, risk difference 12% (95%CI 8.9%-16%). 23 children developed severe anaemia (17 (2.9%) treated with CD and 6 (1.0%) with AL, risk difference 1.8%, 95%CI 0.3%-3.4%, P = 0.02). Haemoglobin concentration on day 3 was lower among children treated with CD than AL (difference 0.43 g/dL, 95% CI 0.24 to 0.62), and within the CD group was lower among those children who had higher parasite density at enrollment. Only 17 out of 1069 children who were typed were G6PD A- deficient, of these 2/9 treated with CD and 1/8 treated with AL developed severe anaemia. 5/9 treated with CD had a fall of 2 g/dL or more in haemoglobin concentration by day 3.

Interpretation: AL was well tolerated and highly effective and when given under operational conditions despite poor adherence to the six-dose regimen. There were more cases of severe malaria and anaemia after CD treatment although G6PD deficiency was uncommon.

Trial registration: Clinicaltrials.gov NCT00118794.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.

References

    1. Lang T, Greenwood BM. The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis 2003; 2003;3:162–68.
    1. World Health Organisation. Information Exchange System Alert No. 117. 2008. QSM/MC/IEA.117. 4th March 2008. WHO: Geneva.
    1. Amukoye E, Winstanley PA, Watkins WM, Snow RW, Hatcher J, et al. Chlorproguanil dapsone: an effective treatment for uncomplicated falciparum malaria. Anti Microb Ag Chemother. 1997;41:2261–64.
    1. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, et al. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet. 2002;360:1136–43.
    1. Winstanley PA, Watkins WM, Muhia D, Szwandt S, Amukoye E, et al. Chlorproguanil-dapsone for uncomplicated falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg. 1997;91:322–27.
    1. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, et al. Comparison of chlorproguanil-dapsone with sulfadoxine pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomized controlled trial. Lancet. 2004;363:1843–48.
    1. Lang T, Hughes D, Kanyok T, Kengeya-Kayondo J, Marsh V, et al. Beyond registration-measuring the public-health potential of new treatments for malaria in Africa. Lancet Infect Dis. 2006;6:46–52.
    1. Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, et al. High Risk of Severe Anaemia after Chlorproguanil-Dapsone+Artesunate Antimalarial Treatment in Patients with G6PD (A-) Deficiency. PLoS ONE. 2008;3(12):e4031. doi: .
    1. Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, et al. Chlorproguanil-Dapsone-Artesunate versus Artemether-Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria. PLoS ONE. 2009;4(8):e6682. doi: .
    1. Amin AA, Hughes DA, Marsh V, Abuya TO, Kokwaro GO, et al. The difference between effectiveness and efficacy of antimalarial drugs in Kenya. Trop Med Int Health. 2004;9:967–74.
    1. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269(22):15419–22.
    1. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, et al. Identification of a new genetic defect responsible for the polymorphism of(S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46(4):594–8.
    1. Greenwood BM, Armstrong J. Comparison of two simple methods for determining malaria parasite density. Trans Roy Soc Trop Med Hyg. 1991;85:186–88.
    1. Duraisingh MT, Curtis J, Warhurst DC. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol. 1998;89:1–8.
    1. Sirugo G, Schaefer EA, Mendy A, Sabeti P, West, B, et al. Is G6PD A- deficiency associated with recurrent stillbirths in The Gambia? Am J Med Genetics. 2004;128A:104–5.
    1. Walton RT, Kimber M, Rockett K, Trafford C, Kwiatkowski D, et al. Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nature Genetics. 2005;37(9):915-6.
    1. Winstanley P. Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Tropical Medicine and International Health. 2001;6(11):952–954.
    1. Centre for the Management of Intellectual Property in Health Research and Development /Public Intellectual Property Resource for Agriculture. Lapdap antimalarial drug: GlaxoSmithKline, WHO-TDR, and the UK Department for International Development. 2007. Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds A Krattiger, RT Mahoney, L Nelsen, et al). MIHR: Oxford, UK and PIPRA: Davis, USA. .
    1. World Health Organisation. Review of the safety of chlorproguanil–dapsone in the treatment of uncomplicated falciparum malaria in Africa. Report of a technical consultation convened by WHO. 2004 World Health Organization. Geneva, 1–2 July 2004. (Accessed 13 July 2006)
    1. Rogers L. The Sunday Times June 12, 2005; 2005. Health experts warn over “dangerous malaria drug.
    1. Van Boxtel CJ, Edwards IR. Lapdap and the Sunday Times–Britain. International Journal of Risk and Safety in Medicine. 2005;17:169–172.
    1. Degowin RL, Bennett Eppes R, Powell R, Carson E. The haemolytic effects of Diaphenylsulfone (DDS) in normal subjects and in those with Glucose-6-phosphate-dehydrogenase deficiency. Bull. Wld. Hlth. Org. 1966;35:165–179.
    1. Luzzatto L. Glucose-6-phosphate dehydrogenase deficiency. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine. Third Ed. Oxford: Oxford University Press, 1998; 1998. pp. 3537–41.
    1. Mockenhaupt FP, Mandelkow J, Till H, Ehrhardt S, Eggelte TA, et al. Reduced prevalence of Plasmodium falciparum infection and of concomitant anaemia in pregnant women with heterozygous G6PD deficiency. Trop Med Int. Health. 2005;10:512–20.
    1. May J, Meyer CG, Grossterlinden L, Ademowo OG, Mockenhaupt FP, et al. Red cell glucose-6-phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population. Trop Med Int Health. 2000;5:119–123.
    1. Vulliamy T, Mason P, Luzzatto L. The molecular basis of glucose-6-phosphate dehydrogenase deficiency. Trends Genet. 1992;8:138–143.
    1. De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, et al. The role of the G6PD AEth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the Seerer population of Senegal. Haematologica. 2006;91:262–263.
    1. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur. J. Hum. Genet. 2009;17:1080–1085.
    1. Beutler E Duparc S; G6PD Deficiency Working Group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77(4):779–89.
    1. Dunyo S, Ord R, Hallett R, Jawara M, Walraven GMesaE, et al. Randomised trial of chloroquine/sulfadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clin Trials. 2006;1:e14.
    1. Schoepflin S, Lin E, Kiniboro B, DaRe JT, Mehlotra RK, et al. Treatment with Coartem (Artemether-Lumefantrine) in Papua New Guinea. Am. J. Trop. Med. Hyg. 2010;82(4):529–534.
    1. Yeung S, White NJ. How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health. 2005;10:121–138.
    1. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. X-Linked G6PD Deficiency Protects Hemizygous Males but Not Heterozygous Females against Severe Malaria. PLoS Med. 2007;4(3):e66. 2007 March;
    1. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet: 2008;372:1819–1827.
    1. Luzzato L. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet. 2010;376:739–41.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다